tbuckley/cabot-search huggingface dataset:
INDIA
Journal: JAMA (1961)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
An Unexpected Burden
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Transactions of the American Association of Obstetricians and Gynecologists, 1889.
Journal: JAMA (1890)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
MEDICAL DEFENSE IN IOWA
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Recycling
Authors: James H. King
Journal: Annals of Internal Medicine (2014)

Letters20 May 2014RecyclingJames H. King, MDJames H. King, MDFrom OSF Galesburg Clinic, Galesburg, Illinois.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/L14-5010-5 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:Dr. Blakely seems to not realize that my commentary was ironic. I don't really think that the patient-centered medical home is indeed synonymous with a multispecialty group practice, but the definition of the medical home that its proponents give is synonymous with a multispecialty practice. The patient-centered medical home is actually an inadequate attempt to deliver primary care by committee without benefit of primary care physicians. This idea is certainly transformative, but the question is, “What is being transformed, and to what is it being transformed?”The definition of “patient-centered care” varies from “the customer is always right” ...Reference1. Bensing J. Bridging the gap. The separate worlds of evidence-based medicine and patient-centered medicine. Patient Educ Couns. 2000;39:17-25. [PMID: 11013544] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: James H. King, MDAffiliations: From OSF Galesburg Clinic, Galesburg, Illinois.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L14-0114. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoRecycling James H. King Recycling Richard Blakely Recycling Edward Volpintesta Metrics 20 May 2014Volume 160, Issue 10Page: 738-739KeywordsAccountable care organizationsDecision makingDisclosureEvidence based medicineLength of stayPatient advocacyPopulation statisticsPrimary care physicians ePublished: 20 May 2014 Issue Published: 20 May 2014 Copyright & PermissionsCopyright © 2014 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Cheaper Antitoxin.
Authors: Heman Spalding
Journal: JAMA (1906)

Chicago, May 21, 1906. <h3>To the Editor:</h3> —The statements inThe Journal, May 12, page 1449, that the Memorial Institute for Infectious Diseases is said to be supplying antitoxin to the city for $1.50 per 3000 units as against $5.25, the sum charged by the alleged antitoxin trust, is misleading, as it compares the purchasing price of the Memorial Institute with the retail price to the general public of the other producers of antitoxin. The statement was not taken from the Chicago<i>Health Department Bulletin</i>, nor did the statement come from me. The correction of the above statement inThe Journalfor May 19, page 1533, gives our purchase and selling prices correctly, $1.50 and $2.25 per 3000 units, and states that other firms have offered the Department of Health antitoxin at practically the same price. This latter statement is true also, but there is a story behind it. All
Specific targeting of adriamycin conjugates with monoclonal antibodies to hepatoma associated antigens to intrahepatic tumors in athymic mice*1
Authors: R ADLER
Journal: Hepatology (1995)

Doxorubicin (adriamycin), once considered the treatment of choice for hepatocellular carcinoma (HCC), is known to cause cardiotoxicity and myelotoxicity. To reduce the systemic toxicity of adriamycin by direct delivery of the drug to the tumor site, we established a panel of monoclonal antibodies (MAbs) to hepatoma associated antigens that were conjugated to adriamycin by a dextran bridge. Initially, the efficacy of these conjugates in suppressing tumor growth was assessed using a model of subcutaneous HCC tumors injected in athymic mice. In the second stage of the study, we tested these conjugates in an experimental model in which human HCC was transplanted intrahepatically by intrasplenic injection, thus providing the tumor cells with growth factors and an adequate cellular matrix, similar to the natural microenvironment of HCC. Anti-tumoral therapy resulted in lower serum alpha-fetoprotein (AFP) levels in two of three experimental groups treated with different specific conjugates as compared with control mice treated with the individual components. Efficacy of targeting was enhanced using the intrahepatic model system for propagation of HCC and was demonstrated by fluorescence of adriamycin and MAb in tumor tissue and absence of this fluorescence in healthy liver tissue surrounding the tumor. Reduction of systemic toxicity was shown by the absence of adriamycin fluorescence in myocardial tissue in conjugate-treated mice, whereas in all other treatment groups, including mice treated with a mixture of adriamycin and specific MAb, there was strong myocardial fluorescence of adriamycin.
一项探索增生性瘢痕与瘢痕疙瘩差异的研究
Authors: G.C. Limandjaja, J.M. Belien, R.J. Scheper, F.B. Niessen, S. Gibbs
Journal: British Journal of Dermatology (2020)

增生性瘢痕和瘢痕疙瘩是隆起性、异常性瘢痕的两种类型。增生性瘢痕生长在原创面边界内,最终生长变小,但瘢痕疙瘩生长超出原创面边界,不自行变小,治疗困难。瘢痕疙瘩通常发生在肤色较深的人。有时仍难以确定隆起的瘢痕是增生性瘢痕还是瘢痕疙瘩。 这项荷兰研究旨在确定这两种异常瘢痕是否都形成,因为它们保留了幼稚化、不成熟瘢痕的特征,而不是以正常的方式成熟。 作者研究了存在于皮肤外层(表皮)和内层(真皮)的细胞类型,发现增生性和瘢痕疙瘩与未成熟瘢痕而不是正常健康瘢痕非常相似,存在两个重要的方面:外层细胞没有适当成熟(外皮蛋白表达增加);正常皮肤的内层细胞表达一种称为 CD34 的蛋白,不具有收缩组织的细胞 (α‐SMA),但在异常瘢痕中,这种情况发生逆转,CD34 缺失,存在收缩细胞 (α‐SMA)。 与异常瘢痕不同,未成熟瘢痕内外层细胞表现为细胞生长增加 (Ki67)。异常瘢痕的外层要厚得多,内层有许多细胞(波形蛋白),但这些细胞已经停止生长(称为 p16)。 根据内层的外观很难将增生性瘢痕与瘢痕疙瘩分开,但增生性瘢痕有更多的细胞收缩,瘢痕疙瘩内层有很厚的结缔组织带。 总之,本研究结果提示,增生性瘢痕和瘢痕疙瘩保持了未成熟瘢痕的特征,不像正常瘢痕那样成熟。 本摘要涉及研究:增生性瘢痕和瘢痕疙瘩未能从 CD34‐α‐平滑肌肌动蛋白 (SMA)+未成熟瘢痕表型进展,并且表现出 α‐SMA 和 p16 表达的梯度差异
Molecular dissection of the mitogenic effect of hepatocytes on cultured hepatic stellate cells*1
Authors: A GRESSNER
Journal: Hepatology (1995)

The activation of proliferation of rat liver hepatic stellate cells (HSC) in cooperation with hepatocytes (PC) was studied using a coculture system and cell-conditioned media, respectively. The proliferation of HSC was followed by incorporation of [3H] thymidine and BrdU into DNA and by DNA content per culture. Strong stimulation of HSC proliferation was noticed under reduced fetal calf serum (FCS) conditions (0.2%) during a 48-hour coculture with PC, rat hepatoma, human hepatoma, and transforming growth factor (TGF)-α-transgenic mouse PC, respectively. The extent of stimulation was frequently higher than that observed by the addition of 10% FCS. Transformed HSC (myofibroblasts) could also be stimulated by cocultured PC, but the magnitude of activation was lower than that of (untransformed) HSC. Using radioreceptor assays, we could demonstrate significant concentrations of insulinlike growth factor (IGF)-1 (300 ng/106 cells × 48 hours) and quite lower concentrations of bFGF and TGF-α in the hepatocyte-conditioned media (PCcM), whereas IGF-2 was not detectable. With anti-IGF-1 neutralizing antibody, the stimulatory activity of PCcM could be reduced by approximately 50%. PCcM, which mimics the effects of cocultures and supports strongly the action of exogenous IGF-1 on HSC proliferation, leaving that of other cytokines (TGF-α, IL1 α, bFGF, aFGF, TNF-α), added either separately or in various combinations, uninfluenced. The latter cytokines were without significant effects on HSC proliferation. The mitogenic activity of cytokine combinations containing IGF-1 could be enhanced severalfold by limiting amounts of PCcM. Maximum stimulation of cell proliferation of 40-fold above control cultures was reached by IGF-1 in combination with TGF-α and bFGF in presence of diluted PCcM, which is approximately 6-fold higher than in the absence of PCcM. [125I] IGF-1 added to PCcM was bound by more than 90% to carrier proteins. The results confirm in cocultures strong mitogenic activation of HSC by PC. It is suggested that IGF1 and respective IGF-binding proteins are of great importance in the mitogenic signal transfer between hepatocytes and hepatic stellate cells.
The effect of acidosis on sympatho-adrenal stimulation. Particular reference to cardiopulmonary bypass
Authors: J. R. Malm
Journal: JAMA (1966)

Stimulation of the the sympatho-adrenal system and catecholamine production are induced by several factors accompanying shock. The role of hypotension in evoking this response has been thoroughly investigated. Stimulation of epinephrine and norepinephrine in response to shock has been previously documented, both in experimental work and in clinical situations.<sup>1</sup>The important role of acidosis has been less well elucidated. This report summarizes recent work in this institution, related to the role of acidosis in the stimulation of a sympathoadrenal system, as measured by plasma catecholamine levels. Three experimental models were studied to elucidate clinical observations made during cardiopulmonary bypass. The first series of experiments previously reported by Manger et al<sup>2</sup>were designed to elucidate the effects of acid-base control on the sympathoadrenal response following irreversible hemorrhagic shock. Shock was produced in mongrel dogs with the preparation described by Wiggers,<sup>3</sup>with maintenance of mean arterial-blood pressure of 50
Trivalent combined measles-mumps-rubella vaccine. Findings in clinical-laboratory studies
Authors: J. Stokes
Journal: JAMA (1971)

Four lots of combined trivalent Moraten measles, Jeryl Lynn mumps, and HPV-77 duck rubella vaccine were administered to a total of 715 children, 7 months to 7 years of age, who were initially without antibody against any of the three viruses. Overall, 96% of the children developed measles hemagglutination-inhibiting, 95% developed mumps neutralizing, and 94% developed rubella hemagglutination-inhibiting antibodies. The most important clinical reaction to the trivalent vaccine was mild fever in a portion of the children, such as is expected following administration of Moraten measles vaccine alone. Joint involvement was notably absent during the six-to-nine week follow-up. The combined measles-mumps-rubella vaccine provides a simple means for immunizing against all three of these diseases without impairment of antibody response and without significant increase in clinical reaction.
Heart Surgery
Authors: Richard S. Blacher
Journal: JAMA (1979)

THERE are few medical procedures more fraught with anxiety for the patient than surgery on the human heart. Because the heart occupies a unique position in the psychic life of man, cardiac surgery becomes an experience for the patient that is qualitatively different from any other surgery. The heart is not only the central organ of the body and historically the seat of emotions, it is the only organ that functions in a dramatic on-off mode. If it beats, one lives; if it stops its beat, one dies. This definition of death as equated with cessation of heartbeat is the prevalent one in our society, despite the more scientific resort to EEG findings. The heart, not the brain, is seen as the indicator of life and death. <h3>Undergoing Surgery</h3> Thus, the patient undergoing cardiac surgery has a different emotional task than the patient dealing with surgery on any other organ.
SWITZERLAND
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Cancer Journal From Scientific American
Authors: Antonija Prelec
Journal: JAMA (1996)

The purpose of<i>Cancer Journal</i>, as stated by the editors, has been not to publish just another journal on cancer, but to respond to the important needs of a broader audience. The editors believe that these needs can best be met in "the forum of an interactive, peer-reviewed, multidisciplinary journal." The editors envisage this new journal as a publication that provides an integrated view of modern oncology, encourages research and reports on new modalities, and provides a place where research on "the interface between the laboratory and clinic is explored and furthered." Thus, the editors intend<i>Cancer Journal</i>to serve as a bridge between the laboratory and clinic, as a link between various subdisciplies of oncology, and as interesting reading for biomedical researchers and for all
Abstract O.40: Persistent Subacute/Chronic Coronary Arteritis in Kawasaki Disease (KD): Histologic, RNA and Protein Evidence
Authors: Anne H Rowley, Kwang-Youn A Kim, Stanford T Shulman, Susan C Baker, Adam J Pink, Nancy Innocentini, Amy Yang, Elfriede Pahl, Michael Carr, Mark W Lingen, Jan M Orenstein
Journal: Circulation (2015)

Introduction: We identified 3 linked KD vasculopathic processes: acute self-limiting necrotizing arteritis, subacute/chronic (SA/C) arteritis and luminal myofibroblastic proliferation, most critically affecting the coronary arteries (CA). SA/C arteritis (lymphocytes, eosinophils, plasma cells) was not previously recognized, and patients with persistent coronary artery aneurysms do not currently receive immunomodulatory therapy after the initial febrile illness. Hypotheses: SA/C arteritis in KD CA is a process of dysregulated innate and adaptive immune responses, and markers of inflammation can be detected in the sera of KD patients with persistently inflamed CAs. Methods: RNA was isolated from paraffin-embedded CA tissues, and real-time RT-PCR arrays performed on samples passing quality control assays. RNA from KD CA with persistent subacute/chronic arteritis (n=7, 5 mo-several yrs after onset, median age=3 yr) and from CA of childhood controls (n=7, median age=10 mo) was assayed, and dysregulated genes determined (&gt;1.5 fold change and q value &lt;0.05). To identify if dysregulated immune markers were detected in sera of KD children with persistent CA aneurysms, ELISA cytokine array for 400 proteins was performed on sera from 4 KD patients with persistently abnormal CA echocardiograms who were otherwise asymptomatic (3-5 yrs after onset, median age 5 yrs) and 4 age/gender matched healthy childhood controls (median age 5 yrs). Results: Ten interferon response genes and 9 Th1/Th2 response genes were upregulated in chronic KD arteritis tissues. ELISA revealed ~40 proteins with at least tenfold dysregulation in sera of KD children with persisting aneurysms compared to matched controls (q-values=0.07), while serum C-reactive protein levels were not different in the 2 groups. Conclusions: Evidence of dysregulated immune responses can be detected in KD CA tissues months to years after onset in patients with persistent CA disease. In addition, we identified many candidate immune biomarkers of chronic KD arteritis. An immune biomarker panel would be useful to identify and monitor patients with persistent coronary arteritis in potential future clinical trials of immunomodulatory therapies for such patients.
Emergency Anaesthesia
Authors: Leonard F. Walts
Journal: JAMA (1966)

More than just a syllabus of emergency anesthesia, this book reviews much of the field of anesthesia, emphasizing emergency problems. Joining the authors are ten other British contributors, each writing in his special field of interest. Out of a total of 20 chapters, the first few consider fundamentals, such as preoperative evaluation, anesthesia apparatus, and techniques of conduction anesthesia. The authors then discuss anesthesia for special emergency operative conditions. Most notable are the sections dealing with anesthesia for abdominal, obstetrical, and major vascular emergencies. There are two excellent chapters on the problems encountered in patients in the extreme age groups. Finally, the book deals with a variety of subjects such as postanesthetic complications and cardiac arrest. Like many British books, this one is well written and a pleasure to read. Although dogmatic, most of the dogma is sound, and, if followed, would result in a minimum of difficulty. There are
ACC/AHA Clinical Performance Measures for Adults With ST-Elevation and Non–ST-Elevation Myocardial Infarction
Authors: Harlan M. Krumholz, Jeffrey L. Anderson, Neil H. Brooks, Francis M. Fesmire, Costas T. Lambrew, Mary Beth Landrum, W. Douglas Weaver, John Whyte, Robert O. Bonow, Susan J. Bennett, Gregory Burke, Kim A. Eagle, Harlan M. Krumholz, Costas T. Lambrew, Jane Linderbaum, Frederick A. Masoudi, Sharon-Lise T. Normand, Ileana L. Piña, Martha J. Radford, John S. Rumsfeld, James L. Ritchie, John A. Spertus
Journal: Circulation (2006)
Assessment of adverse reactions within a drug surveillance program
Authors: I. T. Borda
Journal: JAMA (1968)

As part of a comprehensive drug surveillance program, we devised a system for identifying and characterizing adverse reactions to drugs. The overall program includes measurements of drug efficacy and a description of the patient population being studied. The data collected thus far suggest that drug reactions represent a major health hazard. Adverse reaction information on any drug must be evaluated for careful consideration of total drug usage, the reasons for prescribing the drug, and its overall efficacy.